Trial Profile
A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Neutropenia; WHIM syndrome
- Focus Adverse reactions; Pharmacodynamics
- 24 Nov 2022 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 24 Nov 2022 Planned primary completion date changed from 31 Jul 2023 to 30 Apr 2024.
- 04 Mar 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.